Narmada Gelatines manufactures and sells gelatin, ossein, and di-calcium phosphate primarily for the pharmaceutical and food industries. The company processes animal bones to create high-grade gelatin used in medicinal capsules and food products.
The company benefits from a narrow moat based on high regulatory barriers and technical certifications (ISO, EDQM, Halal) required for pharmaceutical-grade gelatin. While ROCE is respectable at 14.4%, the lack of significant margin expansion and the commodity-like nature of the raw material inputs suggest limited pricing power.
Management maintains a very conservative, debt-free balance sheet. In FY23, they distributed a massive special dividend (1000%) following a change in promoter control, indicating a shift toward returning cash to owners rather than aggressive reinvestment in growth.
The investment collapsed as the new promoter group shifted the company's focus from operational excellence to serving as a cash cow for related entities. The massive special dividend was not a sign of strength but the beginning of a capital-stripping phase that left the single Jabalpur facility under-maintained and unable to meet tightening pharmaceutical standards. As raw material costs for bone chips spiked due to supply chain shifts, the company lacked the scale or geographic diversity to protect its margins, leading to a permanent impairment of earnings power and a flight of minority shareholders wary of the opaque related-party dealings.
RichFakir rates Narmada Gelatines Ltd's business quality as decent — 57/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Narmada Gelatines Ltd is trading about 15% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Narmada Gelatines Ltd is: Watch — wait for price. A decent business, but at a fair price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Narmada Gelatines Ltd's fair value is about ₹488 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →